FIG. 03 / DOSE CONTEXT
PT-141 dosage, study-attributed: what was given, to whom, by which route — not a recommendation.
The approved label dose for women, the Phase 2 dose-finding range, and the discontinued intranasal research. No instructions.
Start here
This page describes doses that were studied or are on the approved label. It is not a how-to and recommends no dose for anyone. PT-141 dosage in the one approved setting is fixed: for premenopausal women with low sexual desire, the label specifies 1.75 mg injected under the skin, as needed, with hard caps — no more than one dose in 24 hours and no more than eight in a month [7].
Why the caps matter: the same brain receptor sits in appetite circuits, and the blood-pressure and pigmentation effects scale with how often it is used [7]. Everything below is reported as "this dose was given to this group by this route," never as guidance.
PT-141 dosage on the approved label
The US prescribing information specifies 1.75 mg subcutaneous, as needed, at least 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than eight doses per month, for the approved HSDD indication in premenopausal women [7]. This is a labelled dose for an approved indication — stated as the label states it, not as a recommendation for any individual. The label also carries the transient-blood-pressure warning and the contraindication in uncontrolled hypertension or known cardiovascular disease [7].
PT-141 dosage for women in the trials
Phase 2 subcutaneous dose-finding in women evaluated 0.75, 1.25, and 1.75 mg before the 1.75 mg dose advanced to the pivotal trials [7]. The RECONNECT Phase 3 program then used 1.75 mg subcutaneous as-needed in 1,267 premenopausal women, meeting both desire and distress endpoints [3]. The 52-week extension continued the same as-needed dose in 684 women with sustained efficacy [4]. PT-141 dosage for women, in other words, converged on a single as-needed dose — not a daily regimen.
Other studied doses and routes
Early intranasal research in men with erectile dysfunction escalated to roughly 7–20 mg, with a statistically significant erectile response above ~7 mg [1]; the intranasal route was later discontinued for pharmacokinetic variability. A Phase 1 metabolic protocol in women used subcutaneous doses up to 2.5 mg, up to three times daily for 15 days — a research protocol only, not an approved or recommended use [7]. Routes studied include subcutaneous (the approved route), intranasal (early, discontinued), and intravenous (early pharmacology) [7]. The cyclic lactam structure confers more stability than linear melanocortin peptides.